0:000:00
<p>Less is more after PCI, the TARGET-FIRST trial, a negative blood pressure trial that is actually positive, aspirin vs OAC for bleeding, AEDs, and Factor XI is not dead yet are the topics discussed by John Mandrola, MD, on this week's podcast.</p> <p><em>This podcast is intended for healthcare professionals only</em>.</p> <p>To read a partial transcript or to comment, visit:</p> <p>https://www.medscape.com/twic</p> <p><strong>I Less is More: TARGET-FIRST</strong></p> <ul> <li><strong>TARGET-FIRST Trial https://www.nejm.org/doi/10.1056/NEJMoa2508808</strong></li> <li><strong>STOPDAPT-2 ACS Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2789701</strong></li> </ul> <p><strong>II A Negative Trial That Is Actually Positive</strong></p> <ul> <li><strong>The RETREAT-FRAIL Study https://www.nejm.org/doi/full/10.1056/NEJMoa2508157</strong></li> </ul> <p><strong>III Major Bleeding With Aspirin vs Apixaban</strong></p> <ul> <li><strong>Subanalysis of ARTESiA https://jamanetwo...